Current Report Filing (8-k)
April 16 2015 - 8:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
April 16, 2015
Date of Report (Date of Earliest Event
Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425 Abrams,
Ville St- Laurent, Quebec, Canada |
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communication pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events - News Release
IntelGenx Announces Analyst Coverage Initiated by Singular
Research
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
Dated: April 16, 2015 |
By: |
/s/ Paul A. Simmons |
|
|
Paul A. Simmons |
|
|
Chief Financial Officer
|
IntelGenx Announces Analyst Coverage Initiated by Singular
Research
SAINT LAURENT, QUEBEC, April 16, 2015 - IntelGenx
Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the Company or IntelGenx)
today announced that Singular Research has initiated analyst coverage on
IntelGenx.
A copy of the research report may be obtained directly from the
analyst at Singular Research by contacting Greg Eisen, CFA, on 626-405-0242 or
at research@singularresearch.com.
All reports on IntelGenx prepared by analysts represent the
views of such analysts and are not necessarily those of IntelGenx. IntelGenx is
not responsible for the content, accuracy or timelines provided by analysts.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery system to
provide zero-order release of active drugs in the gastrointestinal tract.
IntelGenx has also developed novel delivery technologies for the rapid delivery
of pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx' development pipeline includes
products for the treatment of indications such as severe depression,
hypertension, erectile dysfunction, migraine, insomnia, CNS indications,
idiopathic pulmonary fibrosis, oncology and pain, as well as animal health
products. More information is available about the company at
www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release and the
OTCQX has neither approved nor disapproved the contents of this press
release.
INVESTOR CONTACT: |
COCKRELL GROUP |
Rich Cockrell |
877-889-1972 |
investorrelations@thecockrellgroup.com |
cockrellgroup.com |
|
COMPANY CONTACT: |
Paul A. Simmons |
Chief Financial Officer |
IntelGenx Technologies Corp.
|
T: +1 514-331-7440
|
F: +1 514-331-0436
|
www.intelgenx.com
|
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Apr 2023 to Apr 2024